

# FLUIDIGM

## Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2019

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019, under Fluidigm's 2017 Inducement Award Plan (Plan), as a material inducement to seven individuals entering into employment with Fluidigm. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 48,900 restricted stock units (RSU Awards). For each employee receiving an RSU Award, 12/48th of the total number of shares of common stock underlying each RSU Award will vest on February 20, 2020, and 3/48th of the shares will vest every three months thereafter until fully vested; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. Vesting of the RSU Awards is subject to the employee continuing to be a service provider through each such vesting date, in addition to other terms and conditions of the Plan.

### About Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit [fluidigm.com](http://fluidigm.com).

Fluidigm and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

### Contact:

Mark Spearman  
Senior Director, Corporate Communications  
Fluidigm Corporation  
650 243 6621  
[mark.spearman@fluidigm.com](mailto:mark.spearman@fluidigm.com)

Source: Fluidigm Corporation

 [LogoPressRelease.jpg](#)

Source: Fluidigm Corporation